Picture loading failed.

Anti-CD37 therapeutic antibody (Pre-made Naratuximab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Naratuximab emtansine | IMGN529 (K7153A) | Debio 1562 | Drug Description. ... The investigational drug is in clinical trials for the potential treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, B-Cell Lymphomas. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-364-1mg 1mg 3090
GMP-Bios-ab-364-10mg 10mg 21890
GMP-Bios-ab-364-100mg 100mg 148000
GMP-Bios-ab-364-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD37 therapeutic antibody (Pre-made Naratuximab biosimilar,Whole mAb ADC)
INN Name Naratuximab
TargetCD37
FormatWhole mAb ADC
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesImmunoGen;Chronic lymphocytic leukaemia
Conditions Approvedna
Conditions ActiveDiffuse large B cell lymphoma;Non-Hodgkin's lymphoma
Conditions DiscontinuedChronic lymphocytic leukaemia
Development Techna